Symphogen is the leader in developing recombinant polyclonal antibodies (rpAb), a new class of biopharmaceuticals for the treatment or prophylaxis of serious human diseases. Symphogen is developing rpAb product candidates for therapeutic areas where there is the highest potential to make a significant impact, either by treating diseases that have not successfully been pursued or by providing improved prophylactic or therapeutic options over current drugs. Recombinant pAb therapies may confer greater efficacy, safety and convenience due to their ability to capture the features of the natural human immune response, making them a potentially more attractive treatment option.

Recombinant polyclonal antibodies hold promise for a range of therapeutic applications. The areas that Symphogen is focusing its drug discovery and development efforts on are the replacement of plasma-derived immunoglobulins, prevention or treatment of infectious disease, and treatment of cancer.